| UHC UMR Medical and Drug | Genetic Testing for Hereditary Cancer – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Immune Globulin (IVIG and SCIG) – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Injectable Dermal Fillers and Bulking Agents – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Lower Extremity Endovascular Procedures – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Medical Benefit Therapeutic Equivalent Medications – Excluded Drugs – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Medical Therapies for Enzyme Deficiencies – Commercial Medical Benefit Drug Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Obstructive and Central Sleep Apnea Treatment – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache) – Commercial and Individual Exchange Medical Policy | 2026-10-01 |
| UHC UMR Medical and Drug | Pharmacogenetic Panel Testing – Commercial and Individual Exchange Medical Policy | 2026-10-01 |